Literature DB >> 28316102

Tumor Suppressor PTPRJ Is a Target of miR-155 in Colorectal Cancer.

Xiao-Fei Zhang1, Rongfu Tu2, Keke Li2, Pengxiang Ye1, Xiaofeng Cui1.   

Abstract

PTPRJ is known for its antiproliferative role. Loss of heterozygosity (LOH) of PTPRJ has frequently been observed in various human cancers including colorectal cancer (CRC), lung cancer, and breast cancer. However, the function and mechanism of PTPRJ in CRC are not well understood. At the present study, we show that ectopic expression of PTPRJ inhibits cell growth, migration, and invasiveness in CRC cell line HCT116. Moreover, PTPRJ inhibits the tumorigenecity of HCT116 in a xenograft tumor model. MiR-155, the well-known oncomiR in CRC, is identified as an upstream factor of PTPRJ. MiR-155 directly binds to the 3' untranslated region of PTPRJ mRNA and suppresses the mRNA and protein levels of PTPRJ. Furthermore, the growth-promoting and AKT signaling activation effect of miR-155 was abrogated by PTPRJ overexpression, and vice versa. Our study reveals the crucial role of miR-155/PTPRJ/AKT axis in proliferation and migration of CRC cells and suggests a therapeutic potential of PTPRJ. J. Cell. Biochem. 118: 3391-3400, 2017.
© 2017 Wiley Periodicals, Inc. © 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  COLORECTAL CANCER; PTPRJ; microRNA-155

Mesh:

Substances:

Year:  2017        PMID: 28316102     DOI: 10.1002/jcb.25995

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  14 in total

1.  Verification of candidate microRNA markers for parathyroid carcinoma.

Authors:  Ya Hu; Xiang Zhang; Ming Cui; Zhe Su; Mengyi Wang; Quan Liao; Yupei Zhao
Journal:  Endocrine       Date:  2018-02-16       Impact factor: 3.633

2.  A Network Pharmacology Approach to Uncover the Molecular Mechanisms of Herbal Formula Ban-Xia-Xie-Xin-Tang.

Authors:  Ming Yang; Jialei Chen; Liwen Xu; Xiufeng Shi; Xin Zhou; Rui An; Xinhong Wang
Journal:  Evid Based Complement Alternat Med       Date:  2018-10-16       Impact factor: 2.629

3.  MiR-155-5p modulates HSV-1 replication via the epigenetic regulation of SRSF2 gene expression.

Authors:  Ziqiang Wang; Kun Li; Xiaoxia Wang; Weiren Huang
Journal:  Epigenetics       Date:  2019-04-05       Impact factor: 4.528

4.  Expression and Role of MicroRNA-663b in Childhood Acute Lymphocytic Leukemia and its Mechanism.

Authors:  Xuehua Liu; Haixia Zhang; Baorong Zhang; Xiaohong Zhang
Journal:  Open Med (Wars)       Date:  2019-11-17

5.  The value of miR-155 as a biomarker for the diagnosis and prognosis of lung cancer: a systematic review with meta-analysis.

Authors:  Chuchu Shao; Fengming Yang; Zhiqiang Qin; Xinming Jing; Yongqian Shu; Hua Shen
Journal:  BMC Cancer       Date:  2019-11-14       Impact factor: 4.430

6.  L1CAM as an E-selectin Ligand in Colon Cancer.

Authors:  Fanny M Deschepper; Roberta Zoppi; Martina Pirro; Paul J Hensbergen; Fabio Dall'Olio; Maximillianos Kotsias; Richard A Gardner; Daniel I R Spencer; Paula A Videira
Journal:  Int J Mol Sci       Date:  2020-11-05       Impact factor: 5.923

Review 7.  The dawn of the liquid biopsy in the fight against cancer.

Authors:  Irma G Domínguez-Vigil; Ana K Moreno-Martínez; Julia Y Wang; Michael H A Roehrl; Hugo A Barrera-Saldaña
Journal:  Oncotarget       Date:  2017-12-08

Review 8.  The Dual Role of MicroRNAs in Colorectal Cancer Progression.

Authors:  Lei Ding; Zhenwei Lan; Xianhui Xiong; Hongshun Ao; Yingting Feng; Huan Gu; Min Yu; Qinghua Cui
Journal:  Int J Mol Sci       Date:  2018-09-17       Impact factor: 5.923

9.  miR‑31 promotes tumorigenesis in ulcerative colitis‑associated neoplasia via downregulation of SATB2.

Authors:  Yan Song; Kui Jiang; Bang-Mao Wang; Wen-Tian Liu; Rui Lin
Journal:  Mol Med Rep       Date:  2020-10-08       Impact factor: 2.952

10.  Comprehensive Analysis of Aberrantly Expressed Competitive Endogenous RNA Network and Identification of Prognostic Biomarkers in Pheochromocytoma and Paraganglioma.

Authors:  Zijun Wang; Yijian Li; Yanjun Zhong; Yinhuai Wang; Mou Peng
Journal:  Onco Targets Ther       Date:  2020-11-06       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.